Medivation, Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008

Jan. 28, 2008 - Medivation, Inc. (Nasdaq: MDVN) announced that, based on its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the Company plans to begin a pivotal confirmatory Phase 3 trial of Dimebon(TM) for mild-to-moderate Alzheimer's Disease in the second quarter of 2008... Medivation's Press Release -

Neuronetrix , COGNISION, Tests New Device to Screen for Alzheimer’s Disease

Jan. 23, 2008 - Researchers at the University of Kentucky Sanders-Brown Center on Aging are launching a clinical trial with Neuronetrix’s innovative brain scanning system, called COGNISION, to screen for Alzheimer’s disease. The study with elderly individuals suspected of having Alzheimer’s disease will involve brainwave assessments using a technology called event-related potentials (ERP’).The primary researchers on the study will be Dr. Charles Smith and Dr. Greg Jicha, both faculty in the Department of Neurology at Kentucky. The study is expected to validate the performance of Neuronetrix’s COGNISION™ system and to demonstrate the system’s applicability in a primary care setting...The COGNISION test is expected to be the first approved Alzheimer’s disease screening test which directly evaluates a patient’s cognitive performance...Neuronetrix' Press Release-

CoMentis , Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy

January 7, 2008 – CoMentis, Inc., a privately held biopharmaceutical company, announced that it has completed a Phase I study of its proprietary, orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer’s disease... CoMentis' Press Release-

Nymox Alzheimer Test, Positive Report

January 09, 2008 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announces the publication of a positive peer-reviewed paper on the clinical utility of the Company’s AlzheimAlert™ urine test as an aid to physicians in the diagnosis of Alzheimer’s disease in the current issue of Expert Review of Molecular Diagnostics (January 2008; 8:21-28). The paper, entitled “Practical utility of urinary assay in the diagnosis of Alzheimer's disease: AlzheimAlert™,” is authored by Ira Goodman, MD, the Director of Neurology, Orlando Regional HealthCare, Florida, and Associate Clinical Professor, Departments of Neurology & Medicine, University of Florida School of Medicine... [PDF] Nymox's Press Release -

Prana, Phase IIa Trial of PBT2 in Alzheimer's Disease Patients

January 2, 2008 – Prana Biotechnology Limited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced it has completed its Phase IIa clinical trial of PBT2 in patients with early Alzheimer's disease...This Phase IIa trial is a double blind, placebo-controlled study exploring the safety and tolerability of PBT2, Prana’s proprietary lead compound. The trial also measured PBT2’s effects on the mechanism and progression of the disease, by investigating biomarkers of Alzheimer's Disease, as well as measures of cognition...Prana's Press Release -

Allon Therapeutics, Phase II clinical trial in Alzheimer’s program

December 18, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced that it has completed patient dosing for its Phase II clinical trial evaluating the safety and efficacy of the Company’s proprietary drug candidate AL-108 in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD)...Allon’s program is also the first clinical program to show an effect in animals on both of the classic hallmarks of Alzheimer’s: Neurofibrillary tangles and amyloid beta plaques... Allon's Press Release -

Elan and Transition Therapeutics, Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease

December 21, 2007 - Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) announced that the first patient has been dosed in a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease... Transition Therapeutics' Press Release - Elan's Press Release -

Elan and Wyeth, Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer’s Disease

December 21, 2007 – Elan Corporation, plc (NYSE: ELN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the first patient in North America (NA) has been dosed as part of a global Phase 3 clinical program for bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer’s disease... Wyeth's Press Release - Elan's Press Release -